Lyophilisation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-11. Numbers and descriptions here follow the published literature rather than marketing material.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Stability depends heavily on physical state. Lyophilized powder held dry, cold and dark retains its content over long periods, whereas dissolved peptide begins to change within days at room temperature. The most cited degradation route is oxidation of the methionine residue, which converts the peptide to a sulfoxide form that elutes differently on chromatography. Hydrolysis of amide bonds and adsorption onto container walls contribute smaller losses. Buffers that exclude oxygen from the headspace slow the oxidation pathway, but no single condition prevents all change indefinitely.
Practical handling follows from those properties. Bulk material is best divided into single-use portions soon after receipt, because each thaw exposes the whole container to moisture and temperature cycling. Vials should be allowed to reach room temperature before opening to prevent condensation on the powder. Low-binding plasticware reduces loss of dilute solutions, and sterile filtration is used when a preparation must remain free of microbial growth. Records of batch number, reconstitution date and storage history are what allow a later analytical result to be interpreted meaningfully.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
At menopause, breast atrophy occurs. The breasts can decrease in size when the levels of circulating estrogen decline. The adipose tissue and milk glands also begin to wither. The breasts can also become enlarged from adverse side effects of combined oral contraceptive pills. The size of the breasts can also increase and decrease in response to weight fluctuations. Physical changes to the breasts are often recorded in the stretch marks of the skin envelope; they can serve as historical indicators of the increments and the decrements of the size and volume of a woman's breasts throughout the course of her life. Breast changes during menopause are sometimes treated with hormone replacement therapy.
In relation to this, MDMA's duration and the offset of its effects appear to be determined more by rapid acute tolerance rather than by circulating drug concentrations. Similar findings have been made for amphetamine and methamphetamine. One mechanism by which tolerance to MDMA may occur is internalization of the serotonin transporter (SERT). Although MDMA and serotonin are not significant TAAR1 agonists in humans, TAAR1 activation by MDMA may result in SERT internalization, for instance in rodents in whom MDMA is a potent TAAR1 agonist. It is thought that brain serotonin levels are depleted after MDMA administration but that levels typically return to normal within 24 to 48 hours.
Once wheat gluten had been isolated as the source of the problems, federal investigators in the United States began to trace the gluten used in the foods. All of the gluten came from ChemNutra's Kansas City warehouse. ChemNutra said it had imported nearly 800 tonnes of wheat gluten from the Xuzhou Anying Biologic Technology Development Company of Xuzhou, Jiangsu, China between 29 November and 8 March. ChemNutra says the gluten came directly from China or from China through the Netherlands, and that the company had received no reports of contamination in the chemical analysis provided by Xuzhou Anying Biologic Technology Development Company. The products were shipped from the company's Kansas City warehouse to several pet food manufacturers and one distributor of pet food ingredients in the US and Canada, including the companies affected by the recall. Xuzhou Anying also exports carrots, garlic, ginger, corn protein powder, vegetables and feed. On 5 April 2007, several days after the United States halted all wheat gluten imports, the Chinese government categorically denied any connection to the North American food poisonings to The New York Times, claiming they had no record of exporting any agricultural products that could have tainted the recalled pet foods, including the wheat gluten that had been the focus of the investigation. The general manager of the Xuzhou Anying Biologic Technology Development Company also denied that they had exported any wheat gluten to North America.
Sources: en.wikipedia.org
=== Alternative therapies === Many people use unproven treatments. Regarding female pattern alopecia, there is no evidence for vitamins, minerals, or other dietary supplements. As of 2008, there is little evidence to support the use of lasers to treat male-pattern hair loss. The same applies to special lights. Dietary supplements are not typically recommended. A 2015 review found a growing number of papers in which plant extracts were studied but only one randomized controlled clinical trial, namely a study in 10 people of saw palmetto extract.
=== EC 1.14.11 With 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors === EC 1.14.11.1: γ-butyrobetaine dioxygenase EC 1.14.11.2: procollagen-proline dioxygenase EC 1.14.11.3: pyrimidine-deoxynucleoside 2′-dioxygenase EC 1.14.11.4: procollagen-lysine 5-dioxygenase EC 1.14.11.5: Now included with EC 1.14.11.6 thymine dioxygenase EC 1.14.11.6: thymine dioxygenase EC 1.14.11.7: procollagen-proline 3-dioxygenase EC 1.14.11.8: trimethyllysine dioxygenase EC 1.14.11.9: flavanone 3-dioxygenase EC 1.14.11.10: pyrimidine-deoxynucleoside 1′-dioxygenase EC 1.14.11.11: hyoscyamine (6S)-dioxygenase EC 1.14.11.12: gibberellin-44 dioxygenase EC 1.14.11.13: gibberellin 2β-dioxygenase EC 1.14.11.14: Now EC 1.14.20.13, 6β-hydroxyhyoscyamine epoxidase EC 1.14.11.15: gibberellin 3β-dioxygenase EC 1.14.11.16: peptide-aspartate β-dioxygenase EC 1.14.11.17: taurine dioxygenase EC 1.14.11.18: phytanoyl-CoA dioxygenase EC 1.14.11.19: Now EC 1.14.20.4, anthocyanidin synthase EC 1.14.11.20: deacetoxyvindoline 4-hydroxylase EC 1.14.11.21: clavaminate synthase EC 1.14.11.22: Now EC 1.14.20.5, flavone synthase EC 1.14.11.23: Now EC 1.14.20.6, flavonol synthase EC 1.14.11.24: 2′-deoxymugineic-acid 2′-dioxygenase EC 1.14.11.25: mugineic-acid 3-dioxygenase EC 1.14.11.26: deacetoxycephalosporin-C hydroxylase EC 1.14.11.27: [histone H3]-dimethyl-L-lysine36 demethylase EC 1.14.11.28: proline 3-hydroxylase EC 1.14.11.29: hypoxia-inducible factor-proline dioxygenase EC 1.14.11.30: hypoxia-inducible factor-asparagine dioxygenase EC 1.14.11.31: thebaine 6-O-demethylase EC 1.14.11.32: codeine 3-O-demethylase EC 1.14.11.33: DNA oxidative demethylase EC 1.14.11.34: Now EC 1.14.20.7, 2-oxoglutarate/L-arginine monooxygenase/decarboxylase (succinate-forming) EC 1.14.11.35: 1-deoxypentalenic acid 11β-hydroxylase EC 1.14.11.36: pentalenolactone F synthase EC 1.14.11.36: pentalenolactone F synthase EC 1.14.11.37: kanamycin B dioxygenase EC 1.14.11.38: verruculogen synthase EC 1.14.11.39: L-asparagine hydroxylase EC 1.14.11.40: enduracididine β-hydroxylase EC 1.14.11.41: L-arginine hydroxylase EC 1.14.11.42: tRNAPhe (7-(3-amino-3-carboxypropyl)wyosine37-C2)-hydroxylase EC 1.14.11.43: (S)-dichlorprop dioxygenase (2-oxoglutarate) EC 1.14.11.44: (R)-dichlorprop dioxygenase (2-oxoglutarate) EC 1.14.11.45: L-isoleucine 4-hydroxylase EC 1.14.11.46: 2-aminoethylphosphonate dioxygenase EC 1.14.11.47: [50S ribosomal protein L16]-arginine 3-hydroxylase EC 1.14.11.48: xanthine dioxygenase EC 1.14.11.49: uridine-5′-phosphate dioxygenase EC|1.14.11.50: Now EC 1.14.20.8, (–)-deoxypodophyllotoxin synthase EC 1.14.11.51: DNA N6-methyladenine demethylase EC 1.14.11.52: validamycin A dioxygenase EC 1.14.11.53: mRNA N6-methyladenine demethylase EC 1.14.11.54: mRNA N1-methyladenine demethylase EC 1.14.11.55: ectoine hydroxylase EC 1.14.11.56: L-proline cis-4-hydroxylase EC 1.14.11.57: L-proline trans-4-hydroxylase EC 1.14.11.58: ornithine lipid ester-linked acyl 2-hydroxylase EC 1.14.11.59: 2,4-dihydroxy-1,4-benzoxazin-3-one-glucoside dioxygenase EC 1.14.11.60: scopoletin 8-hydroxylase EC 1.14.11.61: feruloyl-CoA 6-hydroxylase EC 1.14.11.62: trans-4-coumaroyl-CoA 2-hydroxylase EC 1.14.11.63: peptidyl-lysine (3S)-dioxygenase EC 1.14.11.64: glutarate dioxygenase EC 1.14.11.65: [histone H3]-dimethyl-L-lysine9 demethylase EC 1.14.11.66: [histone H3]-trimethylL-lysine9 demethylase EC 1.14.11.67: [histone H3]-trimethyl-LL-lysine4 demethylase EC 1.14.11.68: [histone H3]-trimethyl-L-lysine27 demethylase EC 1.14.11.69: [histone H3]-trimethyl-L-lysine37 demethylase EC 1.14.11.70: 7-deoxycylindrospermopsin hydroxylase EC 1.14.11.71: methylphosphonate hydroxylase EC 1.14.11.72: [2-(trimethylamino)ethyl]phosphonate dioxygenase EC 1.14.11.73: [protein]-arginine 3-hydroxylase EC 1.14.11.74: L-isoleucine 31-dioxygenase EC 1.14.11.75: 31-hydroxy-L-isoleucine 4-dioxygenase EC 1.14.11.76: L-glutamate 3(R)-hydroxylase EC 1.14.11.77: alkyl sulfatase
=== Externally directed self-assembly === The natural ability of nanoparticles to self-assemble can be replicated in systems that do not intrinsically or spontaneously self-assemble. Directed self-assembly (DSA) attempts to mimic the chemical properties of self-assembling systems, while simultaneously controlling the thermodynamic system to maximize self-assembly. However, many common routes to externally promote self-assembly occur far from thermodynamic equilibrium and are rather described by kinetic theories.
== Metabolism == Metabolism of 1,3-dibromopropane was examined in 1981. The examination was done by orally administering 1,3-dibromopropane to rats and collecting results 24 hours after administration. Results were obtained from three sources: urine, faeces, and expired air. Upon analysis of the urinary results, researchers discovered the formation of metabolite, N-acetyl-S-(1-bromo-3-propyl)-cysteine and the decline in the GSH content of the liver of the rats. This led to the assumption that 1,3-dibromopropane could have reacted with GSH after administration and gave rise to 1-bromo-3-propyl-S-glutathione, which ultimately form the urinary metabolite. Moreover, due to little radioactivity observed from feces and the confirmation from maintained blood levels of radioactivity proved the occurrence of biliary excretion of sulfur-containing metabolites and enterohepatic cycling.
Sources: en.wikipedia.org
By the late 20th century, new fields like genomics and proteomics were reversing this trend, with organismal biologists using molecular techniques, and molecular and cell biologists investigating the interplay between genes and the environment, as well as the genetics of natural populations of organisms.
=== VGLUTs === Three types of vesicular glutamate transporters are known, VGLUTs 1–3 (SLC17A7, SLC17A6, and SLC17A8 respectively) and the novel glutamate/aspartate transporter sialin. These transporters pack the neurotransmitter into synaptic vesicles so that they can be released into the synapse. VGLUTs are dependent on the proton gradient that exists in the secretory system (vesicles being more acidic than the cytosol). VGLUTs have only between one hundredth and one thousandth the affinity for glutamate that EAATs have. Also unlike EAATs, they do not appear to transport aspartate.
== Epidemiology == In a study in British Columbia, the overall incidence of the inborn errors of metabolism were estimated to be 40 per 100,000 live births or 1 in 2,500 births, overall representing more than approximately 15% of single gene disorders in the population. While a Mexican study established an overall incidence of 3.4:1,000 live newborns and a carrier detection of 6.8:1,000 NBS.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
Each freeze-thaw cycle can degrade a fraction of the peptide and promote aggregation. Dividing a stock solution into single-use volumes removes repeated cycling as a variable. It also limits the time a thawed solution spends at room temperature.